Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

QIAGEN Elevates Cancer Research Portfolio with Newest Product Unveilings at AACR Annual Meeting 2024

NextEdge Admin

04 Apr 2024

3 min 35 sec

QIAGEN has unveiled a suite of groundbreaking products aimed at revolutionizing cancer research and liquid biopsy techniques, presented at the American Association for Cancer Research (AACR) annual meeting. These innovations promise to significantly advance cancer detection, monitoring, and treatment.

The newly launched QIAcuity dPCR PanCancer Kits represent a major leap forward in mutation detection. Designed for use with QIAGEN’s QIAcuity dPCR system, these kits enable researchers to detect multiple EGFR and BRAF mutations simultaneously with unprecedented sensitivity. By offering enhanced specificity and reducing false positives, these assays accelerate early mutation detection and screenings, potentially transforming prognostic and predictive biomarker analysis.

Complementing this, the QIAseq Targeted RNA-seq Panel for T-cell receptors facilitates accurate characterization of the immune repertoire, shedding light on how T-cell receptors interact with cancer cells. This panel utilizes unique molecular indices (UMI) and QIAseq Enrichment Technology to enable ultrasensitive and accurate detection of T-cell receptors, aiding research into utilizing the immune system to combat cancer.

In collaboration with PreAnalytiX, QIAGEN has developed the PAXgene Urine Liquid Biopsy Set, addressing current workflow gaps in urine-based liquid biopsy. By preventing the degradation of cell-free DNA (ucfDNA) in urine samples, this set enables reliable analysis for detecting minimal residual disease and monitoring treatment response. This complements traditional blood plasma analysis, offering a more comprehensive understanding of the tumor and enhancing patient care.

Additionally, the upcoming launch of the QIAcuity system for in vitro diagnostic (IVD) testing represents a significant milestone, extending QIAGEN’s digital PCR technology into clinical settings. This system offers a simplified yet regulatory-compliant route for running IVD assays or lab-developed tests (LDTs), promising faster turnaround times and improved diagnostic accuracy.

Professor Ellen Heitzer’s study highlights the significance of QIAGEN’s urine collection and stabilization solution, which optimizes standardized workflows for ucf DNA analysis. This solution opens avenues for various downstream analyses, providing crucial complementary information for cancer research and ultimately improving patient outcomes.

QIAGEN’s innovative products showcased at the AACR meeting underscore its commitment to providing Sample to Insight solutions. By enabling researchers and clinicians to glean valuable molecular insights from diverse sample types, QIAGEN is at the forefront of driving advancements in cancer research and patient care